Kezar Life Sciences, Inc. (KZR)

Kezar Life Sciences Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Cash & Equivalents	71.88	41.75	35.49	40.46	62.88
Short-Term Investments	-	90.5	165.88	236.11	145.47
Cash & Short-Term Investments	71.88	132.25	201.37	276.56	208.36
Cash Growth	-45.65%	-34.33%	-27.19%	32.73%	48.35%
Other Current Assets	3.85	5.24	5.58	9.16	3.3
Total Current Assets	75.73	137.49	206.95	285.72	211.65
Net Property, Plant & Equipment	0.92	4.78	8.69	13.17	6
Other Long-Term Assets	-	2.42	5.6	0.67	0.28
Total Assets	76.65	144.68	221.24	299.57	217.93
Accounts Payable	0.51	3.65	8.25	2.48	2.03
Accrued Expenses	3.74	7.94	6.48	5.95	4.99
Short-Term Debt	-	5.22	-	-	-
Current Portion of Leases	2.33	3.53	3.01	2.57	1.2
Other Current Liabilities	3.74	7.94	6.48	5.95	4.99
Total Current Liabilities	6.57	20.33	17.74	11	8.21
Long-Term Debt	-	5.11	10.07	9.83	9.62
Long-Term Leases	-	2.33	5.85	8.87	3.22
Total Long-Term Liabilities	-	7.44	15.92	18.7	12.85
Total Liabilities	6.57	27.77	33.67	29.7	21.06
Common Stock	0.01	0.01	0.01	0.07	0.06
Additional Paid-in Capital	560.6	551.57	538.46	519.62	377.77
Accumulated Other Comprehensive Income	-	-0.16	-0.13	-0.92	-0.29
Retained Earnings	-490.53	-434.5	-350.76	-248.89	-180.65
Shareholders' Equity	70.07	116.92	187.57	269.87	196.88
Total Liabilities & Equity	76.65	144.68	221.24	299.57	217.93
Total Debt	2.33	16.18	18.93	21.26	14.04
Net Cash (Debt)	69.55	116.07	182.44	255.3	194.31
Net Cash Growth	-40.08%	-36.38%	-28.54%	31.39%	43.95%
Net Cash Per Share	9.51	15.92	25.14	37.90	36.83
Book Value	70.07	116.92	187.57	269.87	196.88
Book Value Per Share	9.58	16.04	25.85	40.06	37.32
Tangible Book Value	70.07	116.92	187.57	269.87	196.88
Tangible Book Value Per Share	9.58	16.04	25.85	40.06	37.32

Updated Dec 31, 2025. Data Source: Fiscal.ai. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q